Find Azelnidipine manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

EU WC

EU WC

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

FDF

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 123524-52-7, 3-(1-benzhydrylazetidin-3-yl) 5-isopropyl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, Calblock, Azelnidipine [inn], Cs-905, Cs 905
Molecular Formula
C33H34N4O6
Molecular Weight
582.6  g/mol
InChI Key
ZKFQEACEUNWPMT-UHFFFAOYSA-N
FDA UNII
PV23P19YUG

Azelnidipine
Azelnidipine is a dihydropyridine calcium channel blocker. It is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan. It has a gradual onset of action and produces a long-lasting decrease in blood pressure, with only a small increase in heart rate, unlike some other calcium channel blockers. It is currently being studied for post-ischemic stroke management.
1 2D Structure

Azelnidipine

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
3-O-(1-benzhydrylazetidin-3-yl) 5-O-propan-2-yl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
2.1.2 InChI
InChI=1S/C33H34N4O6/c1-20(2)42-32(38)27-21(3)35-31(34)29(28(27)24-15-10-16-25(17-24)37(40)41)33(39)43-26-18-36(19-26)30(22-11-6-4-7-12-22)23-13-8-5-9-14-23/h4-17,20,26,28,30,35H,18-19,34H2,1-3H3
2.1.3 InChI Key
ZKFQEACEUNWPMT-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=C(C(C(=C(N1)N)C(=O)OC2CN(C2)C(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC(C)C
2.2 Other Identifiers
2.2.1 UNII
PV23P19YUG
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 3-(1-diphenylmethylazetidin-3-yl)-5-isopropyl-2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate

2. Cs 905

3. Cs-905

2.3.2 Depositor-Supplied Synonyms

1. 123524-52-7

2. 3-(1-benzhydrylazetidin-3-yl) 5-isopropyl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

3. Calblock

4. Azelnidipine [inn]

5. Cs-905

6. Cs 905

7. Pv23p19yug

8. Ncgc00167436-01

9. Ncgc00167436-02

10. Dsstox_cid_120

11. Dsstox_rid_75382

12. Dsstox_gsid_20120

13. 3,5-pyridinedicarboxylic Acid, 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-[1-(diphenylmethyl)-3-azetidinyl] 5-(1-methylethyl) Ester

14. 3-o-(1-benzhydrylazetidin-3-yl) 5-o-propan-2-yl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

15. Cas-123524-52-7

16. Unii-pv23p19yug

17. Rs-9054

18. Ccris 8650

19. Calblock (tn)

20. Mfcd00865803

21. Azelnidipine [mi]

22. Azelnidipine [jan]

23. Azelnidipine (jp17/inn)

24. Schembl49021

25. Azelnidipine [mart.]

26. 2-amino-1,4-dihydro-6-methyl-4-(3 Nitrophenyl)-3,5-pyridinedicarboxylic Acid 3-[1-(diphenylmethyl)-3-azetidinyl] 5-(1-methylethyl) Ester

27. 3,5-pyridinedicarboxylic Acid, 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-(1-(diphenylmethyl)-3-azetidinyl) 5-(1-methylethyl) Ester, (+-)-

28. Azelnidipine [who-dd]

29. Chembl1275868

30. Dtxsid3020120

31. Chebi:31247

32. Bcpp000357

33. Hms3651d18

34. Hms3885m05

35. Amy22122

36. Hy-b0023

37. Tox21_112440

38. S3053

39. Akos015841674

40. Tox21_112440_1

41. Ac-2151

42. Bcp9000370

43. Ccg-270140

44. Cs-0949

45. Db09230

46. Ks-1248

47. Pb24693

48. Azelnidipine, >=98% (hplc), Powder

49. 3,5-pyridinedicarboxylic Acid, 1,4-dihydro-2-amino-6-methyl-4-(3-nitrophenyl)-, 3-(1-(diphenylmethyl)-3-azetidinyl) 5-(1-methylethyl) Ester, (+-)-

50. 3,5-pyridinedicarboxylic Acid, 1,4-dihydro-2-amino-6-methyl-4-(3-nitrophenyl)-, 3-(1-(diphenylmethyl)-3-azetidinyl)-5-(1-methylethyl) Esster, (+-)-

51. 3-(1-(diphenylmethyl)-3-azetidinyl) 5-isopropyl (+-)-2-amino-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate

52. 3-[1-(diphenylmethyl)azetidin-3-yl] 5-(1-methylethyl) 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

53. Ft-0655294

54. Sw219236-1

55. D01145

56. Ab01565841_02

57. 524a527

58. A805113

59. Sr-01000944916

60. Q-200664

61. Q4832365

62. Sr-01000944916-1

63. (+/-)-2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic Acid 3-(1-diphenylmethylazetidin-3-yl) Ester 5-isopropyl Ester

64. 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic Acid 3-(1-diphenylmethylazetidin-3-yl)ester 5-isopropyl Ester

65. 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic Acid 3-[1-(diphenylmethyl)-3-azetidinyl] 5-isopropyl Ester

66. 3-(1-(diphenylmethyl)-3-azetidinyl) 5-isopropyl (+/-)-2-amino-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate

67. 3-[1-(diphenylmethyl)-3-azetidinyl] 5-isopropyl 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate

68. O3-(1-benzhydrylazetidin-3-yl) O5-isopropyl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;azelnidipine

2.4 Create Date
2005-06-24
3 Chemical and Physical Properties
Molecular Weight 582.6 g/mol
Molecular Formula C33H34N4O6
XLogP36
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count9
Rotatable Bond Count10
Exact Mass582.24783482 g/mol
Monoisotopic Mass582.24783482 g/mol
Topological Polar Surface Area140 Ų
Heavy Atom Count43
Formal Charge0
Complexity1080
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

For the treatment of hypertension.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Azelnidipine is a vasodilator that induces a gradual decrease in blood pressure in hypertensive patients. Unlike other members of its drug class, azelnidipine does not induce reflex tachycardia due to vasodilation. This is likely due to the fact that it elicits a gradual fall in blood pressure It also exhibits a prolonged hypotensive effect and has been shown to have a strong anti-arteriosclerotic action in vessels due to its high affinity for vascular tissue and antioxidative activity. Clinical studies have demonstrated that azelnidipine markedly reduced heart rate and proteinuria in hypertensive patients by inhibiting sympathetic nerve activity. Azelnidipine has also been confirmed to have cardio-protective, neuroprotective, and anti-atherosclerotic properties, and has also been found to prevent insulin resistance.


5.2 Absorption, Distribution and Excretion

Absorption

Oral ingestion of azelnidipine demonstrates rapid and dose-dependent absorption.


Route of Elimination

In one study, following a single 4mg oral dose of 14C-labeled azelnidipine in humans, about 26% of the drug was thought to br excreted in the urine and 63% in the feces during the 1 week period post administration.


Volume of Distribution

In a Chinese study examining the pharmacokinetics of the drug, the volume of distribution was found to be 1749 +/- 964.


5.3 Metabolism/Metabolites

Like most members of its class, azelnidipine primarily undergoes first-pass hepatic metabolism. Azelnidipine is metabolized by hepatic cytochrome P450 (CYP) 3A4 and has no active metabolite product. It may interact with other drugs or compounds that are substrates for this enzyme. Azelnidipine is lipophilic and has a potent affinity for membranes of vascular smooth muscle cells.


5.4 Biological Half-Life

16 28 hours.


5.5 Mechanism of Action

Azelnidipine inhibits trans-membrane Ca2+ influx through the voltage-dependent channels of smooth muscles in vascular walls. Ca2+ channels are classified into various categories, including L-type, T-type, N-type, P/Q-type, and R-type Ca2+ channels. The L-type Ca2+ channels. Normally, calcium induces smooth muscle contraction, contributing to hypertension. When calcium channels are blocked, the vascular smooth muscle does not contract, resulting in relaxation of vascular smooth muscle walls and decreased blood pressure.


Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty